No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMGN Amgen
- 309.410
- -5.440-1.73%
Close May 22 16:00 ET
- 308.690
- -0.720-0.23%
Post 19:38 ET
165.98BMarket Cap44.20P/E (TTM)
315.000High308.525Low2.85MVolume314.700Open314.850Pre Close885.62MTurnover0.53%Turnover Ratio24.77P/E (Static)536.43MShares324.85052wk High33.05P/B165.50BFloat Cap205.29152wk Low8.64Dividend TTM534.89MShs Float324.850Historical High2.79%Div YieldTTM2.06%Amplitude8.006Historical Low310.838Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Alvotech Shares up 2.1% as Co Enters Into Agreement With DR Reddy's to Commercialize Biosimilar to Amgen's Bone Disease Drugs Prolia and Xgeva
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.07% on an annualized basis producing an average annual return of 9.12%. Currently, Amgen has a market capitalization of $168
Barclays Sticks to Its Hold Rating for Amgen (AMGN)
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COP
AstraZeneca, Amgen Release Mid-stage Data on Tezspire for COPD
HSBC Adjusts Price Target on Amgen to $356 From $322
Amgen (AMGN) has an average outperform rating and a price target range of $170 to $380, according to analysts polled by Capital IQ. Price: 312.94, Change: +0.47, Percent Change: +0.15
Comments
📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : Review extended to 8/14/24 🤔
⇒ YORV...
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : Review extended to 8/14/24 🤔
⇒ YORV...
10
$Amgen(AMGN.US$ 🤔$450-$475? Friday?🤑🤑🤑All Money In
2
Morning mooers! It is Friday, May 3rd, and the market green after a jam-packed Q1 earnings week.
This time around, FOMC nonaction and low jobs numbers helped push equities in the green, or it migh just be because April is finally over. My name is Kevin Travers, here are stories moving the market:
MOOVERS
$Amgen (AMGN.US)$'s stock soared 12% toward biggest gain in 15 years, adding more than 220 points to the...
This time around, FOMC nonaction and low jobs numbers helped push equities in the green, or it migh just be because April is finally over. My name is Kevin Travers, here are stories moving the market:
MOOVERS
$Amgen (AMGN.US)$'s stock soared 12% toward biggest gain in 15 years, adding more than 220 points to the...
7
5
2
Morning Movers
Gapping up
$Apple(AAPL.US$ rose by 7% after the company reported a decline in revenue in the first quarter of the year but still exceeded analysts' projections. The tech giant also announced a $110 billion stock buyback program and raised its dividend by 4%.
$Amgen(AMGN.US$ soared by 13% after the company expressed encouragement upon completing an interim analysis of its mid-stage study of the weight-loss drug M...
Gapping up
$Apple(AAPL.US$ rose by 7% after the company reported a decline in revenue in the first quarter of the year but still exceeded analysts' projections. The tech giant also announced a $110 billion stock buyback program and raised its dividend by 4%.
$Amgen(AMGN.US$ soared by 13% after the company expressed encouragement upon completing an interim analysis of its mid-stage study of the weight-loss drug M...
23
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
